Growing data link specific genomic lesions to TMB levels, immune contexture, and prognosis in lung cancer.[25] Incorporating TMB and genomic-instability markers into PTLC evaluation may refine prognostic stratification and identify patients who could benefit from immunotherapy or combinatorial strategies, particularly when EGFR-targeted therapy fails.[26]. The gene discussed is EGFR; the disease is lung carcinoma.